


PHARMACEUTICAL 2022

Synaptogenix Inc. Rank 214 of 475





PHARMACEUTICAL 2022

Synaptogenix Inc. Rank 214 of 475

The relative strengths and weaknesses of Synaptogenix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synaptogenix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 241% points. The greatest weakness of Synaptogenix Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 200% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	35,504
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,995
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	7.1
Property and Equipment	20
Research and Development	4,336
Revenues	0
Selling, General and Administrative Expense	8,282

Output Variable	Value in 1000 USD
Assets	35,525
Liabilities	1,995
Expenses	12,618
Stockholders Equity	33,530
Net Income	-12,611
Comprehensive Net Income	-12,611
Economic Capital Ratio	-76%